Cytokinetics Inc
NASDAQ:CYTK

Watchlist Manager
Cytokinetics Inc Logo
Cytokinetics Inc
NASDAQ:CYTK
Watchlist
Price: 37.18 USD -1.98% Market Closed
Market Cap: 4.4B USD

Net Margin
Cytokinetics Inc

-3 201.5%
Current
-5 887%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 201.5%
=
Net Income
-615.3m
/
Revenue
19.2m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Cytokinetics Inc
NASDAQ:CYTK
4.4B USD
-3 201%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
7%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 848%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
17%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
21%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
-9%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
129.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
32%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

Cytokinetics Inc
Glance View

Cytokinetics Inc., rooted firmly in the heart of California's biotechnology hub, has carved a niche in the complex arena of muscle biology. Founded in 1998, the company has focused its considerable expertise on the intricacies of muscle function, especially targeting conditions characterized by impaired muscle performance such as heart failure, ALS, and even SMA. Rather than pursuing the well-trodden paths of traditional pharmaceuticals, Cytokinetics delves into the uncharted realms of muscle contractility, leveraging its proprietary muscle biology expertise to develop small molecule therapeutics. Their pipeline is rich with candidates that promise to enhance muscle function, representing a blend of hope and scientific innovation for conditions that, until now, have seen few breakthroughs. As a business, Cytokinetics operates at the confluence of innovative science and strategic partnerships. Financially, the company nurtures its pipeline through the judicious blend of equity financing, collaboration revenues, and milestone payments. Strategic alliances with larger pharmaceutical companies, such as collaborations previously established with Amgen and Astellas, play a pivotal role; these partnerships not only provide capital but also benefit from shared resources and expanded market reach. With therapies still largely in development, the company's revenue streams are intertwined with the success of clinical trials and approvals, rendering each scientific step a potential catalyst for investor interest and market value growth.

CYTK Intrinsic Value
36 USD
Overvaluation 3%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-3 201.5%
=
Net Income
-615.3m
/
Revenue
19.2m
What is the Net Margin of Cytokinetics Inc?

Based on Cytokinetics Inc's most recent financial statements, the company has Net Margin of -3 201.5%.

Back to Top